Caris Life Sciences®, headquartered in Irving, TX, has announced its participation in the 2024 SGO Annual Meeting on Women's Cancer, happening in San Diego from March 16 to 18. The company, along with its collaborators within the Caris Precision Oncology Alliance™ (POA), will present three studies focusing on various gynecological tumor types.
The studies leverage Caris' extensive multi-modal database, analyzing every gene, to offer insights into cancer that could significantly impact patient diagnosis, prognosis, care plans, and treatment responses.
"We are proud to return and present an array of precision oncology research at this year's SGO Annual Meeting. The findings represent important observations in various gynecological malignancies, including the effect of molecular subtype on survival in uterine carcinosarcoma, identification of potential prognostic biomarkers in ovarian cancer, and an exploration of the frequency and outcomes of endometrial tumors with alterations in multiple molecular classifiers," said Caris EVP and Chief Medical Officer George W. Sledge, Jr., MD. "We are confident that Caris' powerful comprehensive molecular profiling, matched clinical outcomes data and in-depth collaborative efforts within our POA member institutions will lead to novel insights into cancer biology, new targeted therapies and ultimately improved outcomes for all patients with gynecological cancers."
The studies to be presented include:
- Survival outcomes according to molecular classification of uterine carcinosarcoma.
- Frequency and outcomes of co-mutations according to ProMisE classifiers in endometrial cancer.
- Molecular characterization of squamous cell ovarian cancers for identification of therapeutic targets.
The research aims to offer novel insights into cancer biology, potentially leading to new targeted therapies and improved outcomes for patients with gynecological cancers.
Caris will provide poster and abstract summaries of the presented research at their booth (#601) during the event. Full abstracts will be available on the Caris website starting March 16.
The Caris Precision Oncology Alliance™ (POA) comprises 91 cancer centers, academic institutions, research consortia, and healthcare systems, including 43 NCI-designated cancer centers. Together, they collaborate to advance precision oncology and biomarker-driven research, with a focus on improving clinical outcomes for cancer patients through innovative research initiatives.
